> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Glaxo/Innoviva Triple Therapy for COPD
- URL: https://www.fdaweb.com/fda-oks-glaxo-innoviva-triple-therapy-for-copd/
- Published: 2017-09-19T12:00:00.000Z
- Updated: 2026-09-14T22:51:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139657

FDA has approved a GlaxoSmithKline and Innoviva NDA for a once-daily, single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), indicated for long-term maintenance treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis or emphysema. The therapy is intended for patients who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations when additional treatment of airflow obstruction is desired or for those who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol, according to the company. Trelegy Ellipta is not indicated for relieving acute bronchospasm or treating asthma.